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Summary Anthracycline antibiotics (ANT), such as doxoru-
bicin or daunorubicin, are a class of anticancer drugs that are
widely used in oncology. Although highly effective in cancer
therapy, their usefulness is greatly limited by their
cardiotoxicity. Possible mechanisms of ANT cardiotoxicity
include their conversion to secondary alcohol metabolites
(i.e. doxorubicinol, daunorubicinol) catalyzed by carbonyl re-
ductases (CBR) and aldo-keto reductases (AKR). These me-
tabolites are suspected to be more cardiotoxic than their parent
compounds. Moreover, overexpression of ANT-reducing en-
zymes (CBR and AKR) are found in many ANT-resistant
cancers. The secondary metabolites show decreased cytotoxic
properties and are more susceptible to ABC-mediated efflux
than their parent compounds; thus, metabolite formation is
considered one of the mechanisms of cancer resistance.
Inhibitors of CBR and AKR were found to reduce the
cardiotoxicity of ANT and the resistance of cancer cells, and
therefore are be ing inves t iga ted as prospect ive
cardioprotective and chemosensitizing drug candidates. In this
review, the significance of a two-electron reduction of ANT,
including daunorubicin, epirubicin, idarubicin, valrubicin,
amrubicin, aclarubicin, and especially doxorubicin, is de-
scribed with respect to toxicity and efficacy of therapy.
Additionally, CBR and AKR inhibitors, including
monoHER, curcumin, (−)-epigallocatechin gallate, resvera-
trol, berberine or pixantrone, and their modulating effect on
the activity of ANT is characterized and discussed as potential
mechanism of action for novel therapeutics in cancer
treatment.
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Introduction
Anthracyclines (ANT) are a class of cell-cycle non-specific
anticancer antibiotics that were first isolated from the
Streptomyces genus in the early 1960s. This highly efficacious
group of drugs have been commonly used in oncology for
over 40 years. The classic ANT, doxorubicin (DOX) and dau-
norubicin (DAUN), were the first ones employed in cancer
treatment and are still frequently used as both monotherapies
or in chemotherapy regimens [1]. Several other ANT have
also been developed as potent anticancer agents, such as
epirubicin, idarubicin, valrubicin, amrubicin, and aclarubicin.
Moreover, there is great interest in the development of novel
ANT as effective chemotherapeutics. However, this group of
drugs is not without flaws. The characteristic and dose-
limiting factor of ANT treatment is its cardiotoxic effect. It
is estimated that in DOX therapy used at approved doses, the
acute form of cardiotoxicity affects ~11% of patients, while
the chronic form affects ~1.7% of patients. ANT-induced
cardiotoxicity is manifested by arrhythmias, myocarditis, di-
lated cardiomyopathy, and congestive heart failure [2]. Many
potential mechanisms of this adverse effect have been postu-
lated, but the etiology remains unclear. Most reports have
focused on theories associated with the generation of reactive
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oxygen species and the disruption of intracellular ferric
homeostasis.
Other studies, however, have postulated that the formation
of ANT metabolites — products of a two-electron reduction
— secondary alcohols, which are reported to be more
cardiotoxic than their parent compounds, are responsible for
these adverse effects [3, 4]. Their generation is catalyzed by
cytosolic enzymes — carbonyl reductases (CBR) and aldo-
keto reductases (AKR). Furthermore, metabolic reduction of
ANT has been identified as an important process underlying
the resistance of cancer cells [5]. As such, CBR and AKR
inhibitors are hypothesized to have cardioprotective and
chemosensitizing properties [6, 7].
To-date, no review article has focused specifically on the
significance of reductive metabolic pathways of ANT in
cardiotoxicity and the development of resistance in cancer
cells. The aim of this paper is to provide a comprehensive
summary of literature relevant to this topic. The data presented
in this article is focused primarily on the most studied ANT,
DOX. However, the importance of reductive metabolism in
for other ANT is also reviewed. Lastly, the cardioprotective
and chemosensitizing activities of reducing enzyme inhibitors
and their potential as drugs is discussed.
Doxorubicinol formation and pharmacokinetics
The main product of a two-electron DOX reduction is
doxorubicinol (DOXol) (Fig. 1). The potential role of this
metabolite in cardiotoxicity was first proposed in the mid-
1980s [3, 4]. While other metabolites are generated at low
levels, DOXol is the main metabolite of DOX. The plasma
level of DOXol in relation to DOX is inconstant and charac-
terized by large inter-individual variability. In a study involv-
ing 18 patients, the average DOXol/DOX AUC (area under
the curve) ratio was 0.514 [8].
The liver is the dominant organ responsible for DOXol
formation, followed by the kidneys [9]. The results of studies
concerning the distribution of DOXol in tissues, especially in
cardiac tissue, are inconclusive. Some studies have found ac-
cumulation of DOXol in the heart [3, 4], while others have not
[10]. A post-mortem study in patients who had received DOX
before death observed that a significantly higher concentration
of DOX and DOXol was found in the myocardium than in
other tissues. The concentration of DOXol in the heart was
comparable to the concentration of DOX [11].
DOX is a well-established substrate of ABC transporters,
and many studies have indicated DOXol is also suitable sub-
strate for ABC-mediated efflux. In clinical trials, co-
administration of the multi-drug resistance (MDR) modula-
tors, such as zosuquidar, with DOX, led to increased exposure
to DOX and DOXol [12]. When applying the classic MDR
modulator, cyclosporine, the AUC of DOX and DOXol in-
creased by 55 and 350%, respectively. Likewise, an exacerba-
tion of treatment toxicity was observed [13].
Preclinical studies have suggested ABC-mediated transport
is important in DOXol distribution. The ABCB1 (P-
glycoprotein) inhibitor, nilotinib, was found to alter DOX
and DOXol distribution in tumor-bearing mice. In particular,
it increased DOXol accumulation in heart tissue, and intensi-
fied necrosis and vacuolization in cardiomyocytes [14]. In
mice lacking ABCB1, prolonged DOX and DOXol exposure
in cardiac tissue, as well as in the brain and the liver, was
observed [15]. Moreover, studies conducted on cells
transfected with ABCB1, have indicated DOXol as a better
substrate than DOX [16].
Co-administration of MDR modulators with DOX had
been found to lead to meaningful changes in DOXol pharma-
cokinetics, especially in its distribution. Increased accumula-
tion of the metabolite in cardiac tissue, may lead to increased
cardiotoxicity of therapy. However, these observations require
clinical confirmation in humans.
DOXol is produced by a two-electron, NADPH-dependent
reduction of the DOX side-chain carbonyl group (C13) to a
secondary alcohol. Two enzymatic pathways for this process
have been postulated, i.e. a reduction catalyzed by carbonyl
reductases and/or by members of aldo-keto reductase family
[17].
Carbonyl reductases
Carbonyl reductases (CBR) are monomeric, cytosolic en-
zymes that belong to the family of short-chain dehydroge-
nases/reductases. CBR catalyze NADPH-dependent reduction
of carbonyls to related secondary alcohols. Four isoenzymes
have been distinguished: CBR1, CBR2, CBR3 and CBR4.
Numerous studies have found CBR1 and CBR3 contribute
to the formation of DOXol [9, 17]. Recently, CBR4 was pro-
posed to have ANT metabolizing properties [18]. Kinetic
studies have found higher intrinsic clearance of DOX by
CBR1 than by CBR3 [9]. The significance of CBR1 in
DOX reduction has been demonstrated in animal models. In
mice with one functional copy of the CBR1 gene, the DOXol/
DOX ratio was ~60% lower as compared to the control group
and the cardiotoxic effects of DOX were also reduced.
Moreover, Cbr1 +/− mice were better protected against
DOX-induced mortality and weight loss than the wild typeFig. 1 Two-electron reduction of DOX
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[19]. While mice with overexpression of human CBR tended
to develop cardiotoxicity more often than the control group
[20].
Single nucleotide polymorphisms (SNP) in CBR have
been investigated in several research studies involving
human subjects and were found to influence the
pharmacokinetics and toxicity of the enzyme. A SNP
in CBR1 increased DOX-related risk of cardiomyopathy
[21], while other SNPs were associated with significant-
ly increased DOX exposures in a population of Asian
cancer patients [22]. Additonally, a SNP in CBR3
increased the risk of cardiomyopathy [21]. The above-
mentioned studies demonstrate that CBR activity influ-
ences DOX pharmacokinetics, metabolism and toxicity.
However, to further confirm this hypothesis, further
studies, especially clinical trials with larger samples
sizes, are required.
Aldo-keto reductases
Aldo-keto reductases (AKR) are a superfamily of NAD(P)H-
dependent oxidoreductases. Similarly to CBR, these enzymes
are monomers which occur in the cytosol and have the ability
to reduce ketones and aldehydes to their corresponding alco-
hols. AKR1C3 (17β-hydroxysteroid dehydrogenase type V)
is considered as the main DOX reductase. Other AKR en-
zymes characterized as DOX reductases mainly belong to
the AKR1 (AKR1A1, AKR1B1, AKR1C2, AKR1B10) and
the AKR7 (AKR7A2) families [9, 18]. Phenobarbital, an
AKR inhibitor, has been shown to influence DOX pharmaco-
kinetics and demonstrate significant cardioprotective proper-
ties in rodents [23].
As with CBR, several SNPs in AKR genes which alter their
enzymatic activity have been identified. These several
AKR1C3 variants showed a significantly weaker ability to
reduce DOX [18], and in patients with such a phenotype,
treatment with DOX was correlated with an increase in objec-
tive response rate (not statistically significant), progression-
free survival, overall survival, and hematological toxicity of
chemotherapy [24].
Which enzyme is a target for modulation of DOX activity?
The enzyme most essential in the process of DOX
reduction is not yet determined. However, this is impor-
tant for the development of novel inhibitors of DOXol
formation. Based on the catalytic efficiency of recombi-
nant enzymes, AKR1C3 has been indicated as the most
effective reductase in two in vitro studies. Other
enzymes with distinguished efficiencies are CBR1,
CBR3, CBR4 and AKR7A2 [18, 21]. However, expres-
sion levels are also an important factor which influences
the significance of enzymes in vivo. The protein level of
CBR1 or AKR7A2 in the heart exceeded the protein
level of AKR1C3 [18]. While level of enzymes in
tumors is inconstant and may be closely related to the
type of neoplasm and its exposure to therapy. Based on
the studies to-date, determination of the most essential
enzyme is not possible.
Cardiotoxic activity of DOX and DOXol
Although many mechanisms have been postulated, the etiol-
ogy of ANT cardiotoxicity remains unexplained. The most
common hypotheses point to the pro-oxidative iron dependent
and independent properties of ANT. However, for the second-
ary alcohol metabolite of DOX, a somewhat different influ-
ence on cardiac tissue has been observed. In isolated rabbit
heart muscle, DOXol depressed systolic myocardial function
30 times more potently than DOX. Moreover, a variable in-
fluence on ion pumps in cardiac muscle has been observed.
DOXol, in contrast to DOX, was a potent inhibitor of Ca2+,
Mg2+, and Na+/K+-ATPases [4, 25]. In another study, DOXol,
at 100 times lower concentration than DOX, was found to
produce a similar contractile depression of a rabbit atria as
DOX. While in the same concentration, it increased calcium
release from sarcoplasmic reticulum vesicles 3–15 times more
potently than DOX [26]. Hanna et al. found a comparable
influence of DOX and DOXol on RyR2 (ryanodine receptor
2) activity, however, only DOXol affected the SERCA2A
(sarco/endoplasmic reticulum Ca2+-ATPase) function. These
proteins, acting as a receptor and an ion pump, respectively,
play a crucial role in regulating the exchange of calcium ions
between cytoplasm and sarcoplasmic reticulum [27]. These
effects may explain the disruption of cytosolic calcium ions
level induced by DOXol. The calcium level is crucial factor in
the function of cardiomyocytes. Calcium ions are the link
between electric stimulation and cell contraction. Moreover,
theymodulate the activity of several proteins, contribute in the
initiation of apoptosis, and play a role in the pathogenesis of
heart diseases [28]. Therefore, disruption of the main calcium
regulatory systems may be considered as one of the most
important mechanisms of DOXol cardiotoxicity.
Interestingly, the redox theory was also found to be
related to the formation of reduced ANT metabolites.
DOXol disunites iron ions (Fe2+) from iron-sulfur clusters
[4Fe-4S] of cytoplasmic aconitase, with its simultaneous
reoxidation to DOX. In contrast to physiological condi-
tions, iron-lacking apoprotein-aconitase was unable to
activate pathways of iron homeostasis and its iron-
reincorporating properties were impaired [29]. These
results suggest DOXol may also participate in the hypoth-
esized mechanisms regarding pro-oxidative and iron-
related mechanisms of DOX cardiotoxicity.
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Significance of DOXol formation in cancer resistance
Resistance to chemotherapeutic drugs has been recognized as
a major factor influencing the failure of cancer therapy and is
an obstacle in successful treatment of numerous types of neo-
plasms. Cancer cell resistance is a significant problem among
patients treated with ANT [12, 13, 30]. A major mechanism
found to play a dominant role in this phenomenon is the active
transport of drugs across the cell membrane. This involves
members of the ABC protein family (ATP-binding cassette)
i.e. proteins that occur in cell membranes. Their role in resis-
tance is based on the efflux of small-molecular compounds out
of the intracellular space. Inhibitors of ABC pumps, such as
ABCB1, have been proposed as compounds which may re-
verse resistance. ABC transporter inhibitors have shown high
efficacy in in vitro and in vivo models, however, in clinical
studies, they were not sufficiently effective to increase the
response to treatment or exhibited adverse reactions [30].
Due to the lack of effective methods which target drug resis-
tance using ABC transporter modulators, research has focused
on other drug targets.
The CBR and AKR enzymes, due to their presumed role in
ANT detoxification in cancer cells, are potential targets for
novel drugs. The secondary metabolites produced by these
enzymes have been found to be less cytotoxic than their parent
compounds. For example, the LC50 values of DOXol were
59–162 times higher than for DOX [5]. Interestingly, in a
study by Heiben et al., DOXol exhibited a one-million times
lower cytotoxicity than DOX in a clonogenic assay [31].
It has been observed that cancer cells exhibit increased
levels of CBR and AKR expression, and these may influence
DOX activity. The relative abundance of CBR and AKR en-
zymes in nine different cell lines were correlated with DOX
cytotoxicity and the rate of DOX reduction. Rapidly metabo-
lizing cells, which had higher levels of AKR and CBR, were
more resistant to DOX than slowly metabolizing cells [5].
Overexpression of DOX-metabolizing enzymes was found
in both primary cancer cells and cell lines. AKR1C3 overex-
pression was shown in explants taken from patients with
breast cancer and in the breast cancer cell line MCF-7 with
developed resistance to DOX [32]. Microarray analysis was
used to compare gene expression between DOX-resistant and
non-resistant MCF-7 cells. The most over-represented genes
in resistant cells were members of the ABC family, as well as
AKR1B10 and AKR1B1 [31]. Furthermore, studies on CBR/
AKR inhibitors have confirmed the chemosensitizing proper-
ties of such compounds.
As previously described, DOXol seems to be more suitable
for ABC-mediated efflux than DOX. A cell line transfected
with the ABCB1 gene, demonstrated 18.9 times higher resis-
tance to DOXol as compared to the parental line. Similar
results were observed with DOX, however, the acquired resis-
tance was lower. Treatment of transfected cells with an ABC
modulator resulted in increased intracellular accumulation of
both DOX and DOXol [16]. In vivo, in tumor-bearing mice,
nilotinib, acting as ABCB1 inhibitor, was found to increase
the accumulation of DOX and DOXol in cancer tissues [14].
This implies that weaker anticancer activity of DOXol may be
related to its increased affinity to ABC transporters, thus lead-
ing to a lower intracellular concentration of the agent. On the
other hand, DOXol has been shown to have significantly low-
er DNA binding activity as compared to DOX. Moreover,
while DOXol is retained in the cytoplasm or lysosomes,
DOX is mainly accumulated in the nucleus [31]. Therefore,
it seems that lower DOXol activity may result from both
changes in molecule interaction with transporters and molec-
ular targets of DOX (Fig. 2).
Other ANT — are their alcohol metabolites
important?
The literature is much poorer in regards to information on
alcohol metabolites of ANT other than DOX. Although
knowledge one these drugs are not comprehensive, general
conclusions can be drawn.
Daunorubicin
Carbonyl reduction is the main pathway of DAUN metabo-
lism. The role of daunorubicinol (DAUNol) formation in the
activity of DAUN has been investigated in several in vitro and
in vivo studies involving cell lines and rodents.
Unlike DAUN, the concentration of DAUNol in cardiac
tissue and plasma of rabbits treated with DAUN was correlat-
ed with decreased papillary muscle contractility. Furthermore,
in contrast to DAUN, the metabolite inhibited calcium uptake
into the cardiac sarcoplasmic reticulum [33]. The influence of
Fig. 2 Decreased activity of DOXol may result from increased efflux,
intracellular distribution outside the nucleus, and decreased affinity to
DNA
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DAUNol on the cytosolic calcium level has been demonstrat-
ed, and it likely occurs through binding of the ANT with
calsequestrin— a calcium binding protein [34].
Studies have indicated DAUNol formation may also play a
role in cancer resistance. After transfection with the CBR1
gene, decreased cytotoxicity of DAUN was observed in
K562 leukemia cells. In these cells, 94% of DAUN was con-
verted to DAUNol after 2 h of incubation [35]. A valuable
study by Varatharajan et al. was conducted on primary acute
myeloid leukemia (AML) cells derived from human patients.
The study demonstrated a correlation between CBR1 and
CBR3 expression, DAUNol intracellular level, and decreased
DAUN cytotoxicity [36]. Studies have shown a correlation
between cytotoxicity and DAUN metabolism in cancer cell
lines. An increased reduction rate results in a decreased re-
sponse of cancer cells to DAUN [5].
Epirubicin
Epirubicin (EPI) differs from DOX only in the conformation
of a carbon atom in a sugar, daunosamine. Pharmacological
significance of EPI reduction is only briefly mentioned in the
literature. The metabolite has been reported to be less cytotox-
ic than EPI [37], suggesting a possible role of reduction in
resistance development. However, this topic needs further
investigation.
Idarubicin
Idarubicinol (IDAol) is the main metabolite of idarubicin
(IDA) in humans. IDA was found to be reduced to IDAol
in a perfused rat heart, and the CBR and AKR inhibitors
rutin and phenobarbital, respectively, decreased IDAol
formation [38]. Weiss et al. in rats observed cardiotoxic
properties of IDAol, via an increased coronary vascular
resistance than that of IDA. IDAol was also more active
in reducing atrial contraction in the perfused rat heart
[39].
Little is known about the role of CBR and AKR in IDA
reduction. AKR1C3 was found to be IDA reductase and was
responsible for IDA-resistance development [40]. However,
cytotoxicity studies with the isolatedmetabolite indicated only
a small decrease in activity as compared to the parent com-
pound, incomparably smaller than DOXol and DAUNol [16,
41].
On the other hand, active efflux of IDAol from
leukemia cells could be inhibited by MDR modulators,
while IDA efflux under the same conditions was not
significantly affected [42]. Also, in K562 cells, resis-
tance acquired by ABCB1 transfection affected IDAol
activity more than IDA activity [41]. It may be conclud-
ed that IDA reduction may play an important role in
resistance, mainly by facilitating drug transport out of
cells.
Valrubicin
Valrubicin (VAL), N-trifluoroacetyladriamycin-14-valerate,
acts as a prodrug. Hydrolysis of the ester bound to active N-
trif luoroacetyladriamycin and valerate allows N-
t r i f luo roace ty lad r i amyc in to be reduced to N-
trifluoroacetyladriamycinol [43]. The pathways involved in
this process are unknown. The reduced metabolite has poten-
tial anticancer activity, however, based on the existing studies,
it is not possible to determine the significance of N-
trifluoroacetyladriamycinol in the overall pharmacological ef-
fect. VAL is used in the treatment of bladder cancer, and thus it
is administered intravesically, with minimal absorption to sys-
temic circulation.
Amrubicin
Amrubicin (AMR) is an ANT used primarily in Japan for
the treatment of lung cancer. Like other ANT, its metabolism
has been found to influence its activity. Surprisingly, the
toxicity induced by the metabolite was associated with he-
matological disturbances rather than with cardiotoxic effects
[44].
The anticancer activity of the AMR alcohol metabolite is
different from other ANT. A significant increase of cytotoxic-
ity after carbonyl reduction has been observed. Amrubicinol
(AMRol) was 5–54 times more potent than AMR against sev-
eral cancer cell lines [45]. An in vivo study with tumor-
bearing xenografts revealed a dependence between AMR ef-
ficacy and intratumoral metabolism of the drug to AMRol
[46].
Similar to IDA, AMRwas resistant against P-glycoprotein-
mediated efflux to a greater extent than AMRol. Cell transfec-
tion with the ABCB1 gene influenced AMRol cytotoxicity
more than the parent molecule [47]. No detailed kinetic stud-
ies with recombinant enzymes, which could indicate the dom-
inant enzymes involved in AMRol formation, have been
conducted.
Aclarubicin
In a review of the literature, no metabolite of aclarubicin
(ACLA) reduced in its aglycone part has been described
to-date. This fact may result from a shift in the carbonyl
group from the side chain to the neighboring additional
side chain (methyl carboxylate moiety). ACLA metabo-
lism is based on modification and cleavages in its sugar
chains, and yields active glycosides and inactive agly-
cones [48].
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CBR and AKR inhibitors as modulators of ANT
activity
Based on CBR- and AKR-mediated production of second-
ary alcohol metabolites of ANT, the inhibitors of these
enzymes have been evaluated as potential cardioprotective
agents, with simultaneous chemosensitizing activity. The
compounds characterized as CBR/AKR inhibitors include
well known agents, already widely studied in pharmaco-
logical research. Some of these agents have been tested in
clinical trials.
Flavonoids, a class of secondary plant and fungus metabo-
lites with a broad spectrum of biological properties, have been
described in many studies as CBR and AKR inhibitors
[49–51] and have synergistic properties with ANT. In a
Structure-Activity Relationship (SAR) analysis involving 27
flavonoids, assisted by molecular docking, Arai et al. found
that the group of flavones (2-phenyl-1-benzopyran-4-one) ex-
hibited the strongest inhibitory properties against CBR1
(Fig. 3). These flavones bind to the CBR1 enzyme through
the hydroxyl groups at C5 and C7, and through the carbonyl
group at C4, however, the 7-hydroxyl group was critical for
potent inhibition. Consequently, the most active compound
was luteolin [49].
The properties of the flavonoid CBR1 inhibitor,
monoHER, a semi-synthetic monohydroxyethyl derivative
of rutoside, were evaluated in a clinical trial in combination
with DOX. Administration ofmonoHER duringDOX therapy
increased the response to treatment in patients with metastatic
soft-tissue sarcoma. However, the number of participants in
this study was very limited [52].
Chalcones (Fig. 3) are nature-derived compounds with a
wide range of biological activities and evident anticancer
properties. A study assessing SARs by Silvestrin et al., based
on the inhibitory properties of 12 chalcone derivatives, indi-
cated the requirement of the hydroxyl group at C4′ to inhibit
the formation of a secondary alcohol. From hydroxyl-
substituted chalcones at C2, C3, C4, C2′ and C4′, the most
active compound was 2′,4′,2-trihydroxychalcone. This com-
pound demonstrated non-competitive inhibitory properties in
heart cytosolic fraction with an IC50 = 21.2 μM (quercetin
IC50 = 13.7 μM) against DOX reduction [53].
(−)-epigallocatechin gallate (EGCG), a catechin derived
from tea (Camleia sinensis), has been described as a CBR1
inhibitor. It decreased the reduction rate of DAUN and in-
duced a 16.2-20.5% enhancement of drug cytotoxicity in hep-
atoma cell lines. This effect did not occur in Hep3B cells with
lower CBR1 expression levels. A co-treatment of xenografts
(mice) with EGCG and DAUN, resulted in a decrease of tu-
mor volume and reduction of cardiotoxicity. EGCG analogues
were assayed, with derivatives without a gallate moiety found
to be much weaker inhibitors [7].
Resveratrol, a stilbenoid from grapes, was characterized as
a mixed-type inhibitor of CBR1 with a Ki = 55.8 μM.
Resveratrol and a series of its analogues (4′-metoxy; 5-
metoxy; 4′-amino) showed comparative inhibitory properties
toward CBR1. However, a 3,5-dimetoxy derivate and resor-
cinol, a moiety of resveratrol, had no inhibitory activity. The
authors concluded that the m-hydroquinonemoiety is required
for inhibitory properties of the molecule, of which one of the
hydroxyl groups is involved in binding with the enzyme [54].
Curcumin (diferuloylmethane) has been employed in can-
cer therapies in human subjects and is a lead structure for
many compounds with anticancer properties. It showed inhib-
itory properties against CBR1 with Ki = 233 nM with a non-
competitive inhibition type [55]. Another nature-derived com-
pound, emodin, showed inhibitory activity toward CBR1
(Ki = 0.219 μM), AKR1B10 (Ki = 0.667 μM) and AKR1C3
(Ki = 5.46 μM), significantly increased cytotoxicity of DAUN
against A549 and HepG2 cell lines, and inhibited DAUNol
formation in lysates obtained from these cells [56].
A pentacyclic triterpenoid, 23-hydroxybetulinic acid,
after intragastric administration in mice, reduced intrinsic
clearance of DOX from the cytosol of liver and heart
cells. It also decreased DOXol concentration in tissues
and exerted cardioprotective effects [5]. Moreover, stud-
ies using a combination of 23-hydroxybetulinic acid with
DOX found synergistic cytotoxic and antitumor proper-
ties [57].
Berberine, an isoquinoline alkaloid, prevented DOX-
induced decrease of body weight and increase of mortality
in male Sprague–Dawley rats. It also decreased the level car-
diac injury biomarkers and ameliorated cardiac dysfunction in
echocardiographic examination. Decreased DOXol formation
and accumulation in the heart were observed during co-
treatment with berberine [58]. Among the 19 other
isoquinoline alkaloids, stylopine and canadine showed inhib-
itory properties toward AKR1C3-mediated reduction of
DAUN [59]. Oracin, also an isoquinoline derivative devel-
oped as an anticancer agent, inhibited DOX reduction in the
cytosol of MCF-7 cells and increased DOX cytotoxicity.
Moreover, in combination with DOX, oracin demonstrated
proapoptotic properties [60].
Inhibitors of carbonyl reducing enzymes were also found
among synthetic structures. An organoselenium drug, ebselen,
Fig. 3 Flavone and chalcone structures
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a cytoprotective, anti-inflammatory and antioxidant agent, has
been found to be a non-competitive inhibitor of DOXol for-
mation in the cytosol [61]. Hydroxy-PP-Me, a derivative of
the Src kinase inhibitor PP2, through CBR1 inhibition, in-
duced a 25% increase of DAUN cytotoxicity in A549 cells
[62]. Inhibitory properties toward reductases were also found
for pixantrone. Pixantrone and its metabolites, especially N-
dealkylated, showed competitive inhibition of DOX reduction
[63]. Phenobarbital, an anxiolytic, anticonvulsant, and seda-
tive drug, influencedDOX reduction in vitro, in heart and liver
cell cytosols; in DOX-treated male Sprague Dawley rats, it
increased AUC and T0,5 of DOX and decreased the serum
creatine kinase (CK) level by approximately 50% [22]. The
structures of the above described compounds are presented in
Fig. 4.
Significant progress in the field of structural biology has
led to the identification of several crystal structures
representing reducing enzymes. Among them, several high-
resolution structures of CBR1 have been solved. The enzymes
were co-crystallized either solely with NADP+/NADPH
Fig. 4 Molecular structures of various CBR and/or AKR inhibitors
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cofactor (PDB ID: 3BHI) [64], or together with glutathione
(crystals 3BHJ and 4Z3D) [64, 65] and its S-hydroxymethyl
derivative (3BHM) [64] and product of formaldehyde adduc-
tion to glutathione, BiGF2 (2PFG) [66]. Crystal structures of
CBR1 were often elucidated together with an inhibitor
hydroxy-PP complexed in the glutathione binding site placed
next to the NADP+ (1WMA [149] and the complexes: 3BHJ
and 3BHM). The experimental structures deposited in the
RCSB PDB database were frequently used in molecular
modeling studies. The exact crystal structures enabled the de-
velopment of various conformational models of the enzyme,
which in turn allowed for defining the common binding mode
of many of the inhibitors.
The molecular requirements for CBR1 inhibitors and
the structural determinants of the enzyme’s active site
might be presented in the example of the 3BHJ crystal
structure. It represents a functionally complete enzyme,
which is complexed with NADP+ cofactor and adjacent
glutathione, which in turn forms adducts with substrates
under physiological conditions. The crystal was obtained
with hydroxy-PP, found between the glutathione binding
site and the NADP+, where residues forming the catalytic
triad are exposed. The three crucial amino acids are as
follows: Tyr193, which transfers electrons from NADPH
to the substrate; Ser139, which stabilizes the carbonyl
moiety substrate; and Lys197, which forms hydrogen
bonds with the nicotinamide ribose moiety (Fig. 5) [62].
Competitive inhibitors interact mainly with Tyr193 and
Ser139, forming hydrogen bonds, as well as additional
aromatic interactions (π-π stacking) with Trp229 [7, 49,
51]. However, 23-hydroxybetulinic acid was found to
interact with Trp229 and Glu270 only [6]. On the other
hand, a non-competitive inhibitor, curcumin, occupied the
binding site of NADPH [55]. Due to the potentially high
compliance of computational models based on crystal
structures with experimental data, molecular modeling
might be regarded as a useful tool for efficiently aiding
in the design of novel enzymatic inhibitors.
Conclusions
Reports of decreased cardiotoxicity of ANT in rodents with
CBR1 gene knockout [19], in rodents co-treated with CBR
and AKR inhibitors [6], and in patients with lower activity
of enzymes [21] provide pharmacological evidence for the
role of selected secondary alcohol metabolites in the develop-
ment of the cardiotoxic effects of ANT. Reducing enzymes
generating secondary alcohol metabolites are overexpressed
in resistant cancer cells, leading to an increased rate of ANT
reduction [5]. Most secondary metabolites have shown lower
cytotoxic activity and increased susceptibility to efflux
through ABC transporters. However, there is very limited data
concerning the significance of reducing enzymes in the resis-
tance observed during clinical treatment. Multiple studies, in-
cluding in vivo models, indicate promising ANT activity-
modulating properties of CBR and AKR inhibitors.
Therefore, a strategy based on inhibition of reductive metab-
olism could be considered as an approach leading to both a
decrease in cardiotoxicity and a decrease in cancer cells
resistance.
In summary, ANT reducing enzyme inhibitors should
be considered as novel resistance revers ing and
cardioprotective agents. As other proposed drugs targeting
various mechanisms of resistance and cardiotoxicity have
thus far not been approved for clinical use, further studies
should investigative the clinical efficacy of these reducing
enzyme inhibitors.
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bound in the active site of the enzyme. Substrate mimic inhibitor OH-PP
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gand binding (within 4 Å from the ligand atoms) are displayed as sticks,
whereas crucial residues, i.e. forming hydrogen bonds (dotted yellow
lines) and π-π stacking (dotted blue lines), are represented as thick sticks
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